ACHN and 786-O cells were incubated with 100 ng/ml IGF-1 for indicated periods of time

ACHN and 786-O cells were incubated with 100 ng/ml IGF-1 for indicated periods of time. expression of 3UTR-less IGF-1R and constitutively active mTORC1. Together, our results identify a reciprocal regulation of IGF-1R levels and miR-214 expression in renal cancer cells independent of VHL status. Our data provide evidence for a novel mechanism for IGF-1R-driven renal cancer cell proliferation involving miR-214 and mTORC1. allele is lost. Apart from inactivated VHL-driven tumorigenesis, IGF-1 signal transduction significantly contributes to the growth of RCC N3-PEG4-C2-NH2 cells and in animal models (6, 7). In fact, increased IGF-1 mRNA and protein levels in the kidney are significantly higher in RCC in humans (8, 9). Similarly, IGF-1 receptor (IGF-1R) expression has also been shown to be significantly associated with increased risk of RCC (10, 11). Also, patients with IGF-1R-positive RCC showed significantly reduced survival rates (12, 13). The dimeric IGF-1R shares significantly high homology with insulin receptor. IGF-1R is produced as a single polypeptide, which is cleaved to form the mature – and -subunits. The -protein represents the transmembrane protein with extracellular domain, whereas the -subunit is exclusively intracellular. The IGF-1 binds to the extracellular domain of -subunit, resulting in heterotetramerization. Upon ligand binding, conformational change in the juxtamembrane domain induces an increase in tyrosine kinase activity of the -subunit, which autophosphorylates specific tyrosine residues in the -subunit. Tyrosine-phosphorylated Rabbit Polyclonal to S6K-alpha2 -subunit recruits the IRS protein through binding to its N-terminal PTB domain. Receptor-bound IRS protein serves as docking sites for the Src homology 2 domain-containing proteins, which trigger signal transduction to induce tumor growth of RCC mainly by two arms, the Ras/MAPK and phosphatidylinositol 3-kinase/Akt pathways (14, 15). Because of significant homology between IGF-1R and insulin receptor, they can form a hybrid receptor, which binds IGF-1 with an affinity similar to that with IGF-1R heterotetramer alone, and can N3-PEG4-C2-NH2 elicit mitogenic signal transduction in tumor cells (14, 15). Therefore, expression of these receptors in the RCC and availability of the ligands will influence the process of tumorigenesis. Because development of small molecular drugs for inhibition of receptor tyrosine kinases is a field of active research, it is important to consider the therapeutic strategies, which will block both IGF-1R and the hybrid receptors. MicroRNAs (miRs) are short non-coding RNAs, which silence mRNAs post-transcriptionally in a sequence-specific manner to regulate gene expression. MicroRNAs have emerged to regulate the expression of more than 30% of mRNAs coded by the genome (16, 17). Thus, they contribute to regulation of many physiologic and pathologic processes, including oncogenesis (18). miRNAs are produced as primary transcripts (pri-miRs) by the RNA polymerase II-mediated transcription of inter- as well as intragenic regions of chromosomal DNA (19). pri-miRs are processed in the nucleus by the RNase III activity of in the microprocessor multiprotein complex to produce short hairpin pre-miRs, which are exported to the cytoplasm by the exportin 5 (19,C21). The pre-miRs are then processed by the dicer exonuclease III activity in a complex containing its partner trans-activation-responsive RNA-binding protein to yield RNA N3-PEG4-C2-NH2 duplexes. Unwinding of the duplex RNA generates the guide strand as an 22-nucleotide-long mature miRNA (19). Mature miRNA then interacts with the Argonaute 2 to form RNA-dependent silencing complex to bind the 3UTR of mRNA with imperfect complementarity to induce suppression of translation and degradation. Expression profiling of miRNAs has been extensively used to understand the progression, development, and invasion of different cancers, including renal cancer (22). Expression of miRNAs has been used to classify the malignant nature of RCC (23). Thus, targeting of specific miRNA(s) may be a therapeutic strategy in RCC. In this study, we identify increased expression of IGF-1R in both VHL-positive and -negative renal cancer cells as compared with the normal proximal tubular epithelial.

Comments are closed.